PROTAC Library

Loading...
E3 Ligase
Target
Molecular Weight
to
Your selection
  • Your selection
Structure Catalog Product Name CAS E3 Ligase Target Inquiry
2-((2,6-Dimethoxy-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)benzyl)amino)-N-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)propyl)acetamide BPL-202493 2-((2,6-Dimethoxy-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)benzyl)amino)-N-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)propyl)acetamide 2674083-43-1

CRBN

PD-L1

 Inquiry

Molecular Weight: 791.86

Molecular Formula: C43H45N5O10

Boiling Point: 1045.0±65.0°C at 760 Torr

Density: 1.304±0.06 g/cm3

Description: It is a proteolysis targeting chimera (PROTAC) that degrades programmed cell death ligand 1 (PD-L1) in vitro and in vivo.
2-((2,6-Dimethoxy-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)benzyl)amino)-N-(5-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)pentyl)acetamide BPL-202494 2-((2,6-Dimethoxy-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)benzyl)amino)-N-(5-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)pentyl)acetamide 2674083-47-5

CRBN

PD-L1

 Inquiry

Molecular Weight: 819.91

Molecular Formula: C45H49N5O10

Boiling Point: 1053.8±65.0°C at 760 Torr

Density: 1.281±0.06 g/cm3

Description: It is a proteolysis targeting chimera (PROTAC) that degrades programmed cell death ligand 1 (PD-L1) in vitro and in vivo.
2-((2,6-Dimethoxy-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)benzyl)amino)-N-(6-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)hexyl)acetamide BPL-202495 2-((2,6-Dimethoxy-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)benzyl)amino)-N-(6-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)hexyl)acetamide 2674083-50-0

CRBN

PD-L1

 Inquiry

Molecular Weight: 833.94

Molecular Formula: C46H51N5O10

Boiling Point: 1057.1±65.0°C at 760 Torr

Density: 1.270±0.06 g/cm3

Description: It is a proteolysis targeting chimera (PROTAC) that degrades programmed cell death ligand 1 (PD-L1) in vitro and in vivo.
3-((2,6-Dimethoxy-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)benzyl)amino)-N-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)propyl)propanamide BPL-202496 3-((2,6-Dimethoxy-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)benzyl)amino)-N-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)propyl)propanamide 2674083-54-4

CRBN

PD-L1

 Inquiry

Molecular Weight: 805.89

Molecular Formula: C44H47N5O10

Boiling Point: 1057.2±65.0°C at 760 Torr

Density: 1.292±0.06 g/cm3

Description: It is a proteolysis targeting chimera (PROTAC) that degrades programmed cell death ligand 1 (PD-L1) in vitro and in vivo.
3-((2,6-Dimethoxy-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)benzyl)amino)-N-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)propanamide BPL-202497 3-((2,6-Dimethoxy-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)benzyl)amino)-N-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)propanamide 2674083-57-7

CRBN

PD-L1

 Inquiry

Molecular Weight: 819.91

Molecular Formula: C45H49N5O10

Boiling Point: 1063.0±65.0°C at 760 Torr

Density: 1.281±0.06 g/cm3

Description: It is a proteolysis targeting chimera (PROTAC) that degrades programmed cell death ligand 1 (PD-L1) in vitro and in vivo.
3-((2,6-Dimethoxy-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)benzyl)amino)-N-(6-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)hexyl)propanamide BPL-202498 3-((2,6-Dimethoxy-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)benzyl)amino)-N-(6-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)hexyl)propanamide 2674083-60-2

CRBN

PD-L1

 Inquiry

Molecular Weight: 847.97

Molecular Formula: C47H53N5O10

Boiling Point: 1069.4±65.0°C at 760 Torr

Density: 1.260±0.06 g/cm3

Description: It is a proteolysis targeting chimera (PROTAC) that degrades programmed cell death ligand 1 (PD-L1) in vitro and in vivo.
N-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanamide BPL-202499 N-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 798.08

Molecular Formula: C37H35Cl3N6O8

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
N-(3-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanamide BPL-202500 N-(3-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 812.11

Molecular Formula: C38H37Cl3N6O8

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
N-(4-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanamide BPL-202501 N-(4-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 826.13

Molecular Formula: C39H39Cl3N6O8

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
N-(5-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanamide BPL-202502 N-(5-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 840.16

Molecular Formula: C40H41Cl3N6O8

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
N-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanamide BPL-202503 N-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 854.19

Molecular Formula: C41H43Cl3N6O8

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
N-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanoyl)piperazin-1-yl)acetamide BPL-202504 N-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanoyl)piperazin-1-yl)acetamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 924.24

Molecular Formula: C43H45Cl3N8O9

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
N-(3-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanoyl)piperazin-1-yl)acetamide BPL-202505 N-(3-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanoyl)piperazin-1-yl)acetamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 938.27

Molecular Formula: C44H47Cl3N8O9

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
N-(4-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanoyl)piperazin-1-yl)acetamide BPL-202506 N-(4-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanoyl)piperazin-1-yl)acetamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 952.29

Molecular Formula: C45H49Cl3N8O9

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
N-(5-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanoyl)piperazin-1-yl)acetamide BPL-202507 N-(5-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanoyl)piperazin-1-yl)acetamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 966.32

Molecular Formula: C46H51Cl3N8O9

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
N-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanoyl)piperazin-1-yl)acetamide BPL-202508 N-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)butanoyl)piperazin-1-yl)acetamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 980.35

Molecular Formula: C47H53Cl3N8O9

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
(E)-N-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enamide BPL-202509 (E)-N-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 796.06

Molecular Formula: C37H33Cl3N6O8

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
(E)-N-(3-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enamide BPL-202510 (E)-N-(3-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 810.09

Molecular Formula: C38H35Cl3N6O8

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
(E)-N-(4-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enamide BPL-202511 (E)-N-(4-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 824.12

Molecular Formula: C39H37Cl3N6O8

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
(E)-N-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enamide BPL-202512 (E)-N-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 852.17

Molecular Formula: C41H41Cl3N6O8

Boiling Point: 1090.3±65.0°C at 760 Torr

Density: 1.420±0.06 g/cm3

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
  • Email:
Copyright © 2024 BOC Sciences. All Rights Reserved.
Inquiry Basket
Loading ......
Delete selectedGo to checkout